
Muvalaplin, a novel oral medication, demonstrates significant potential in safely and effectively reducing Lp(a) cholesterol levels, a key risk factor for cardiovascular disease, as evidenced by the phase 2 KRAKEN trial.


coremsg

Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk and for which no approved therapies currently exist.

New Pill Successfully Lowers Lp(a) Levels

muvalaplin-shows-promise-in-lowering-lp-a-cholesterol-results-from-the-phase-2-kraken-trial


Muvalaplin Shows Promise in Lowering Lp(a) Cholesterol: Results from the Phase 2 KRAKEN Trial
